phensuximide (milontin) Report issue

Small molecule Approved FDA Priority Review FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Phensuximide is an anticonvulsant in the succinimide class. For the treatment of epilepsy. Phensuximide suppresses the paroxysmal three cycle per second spike and wave EEG pattern associated with lapses of consciousness in absence (petit mal) seizures. The frequency of attacks is reduced by depression of nerve transmission in the motor cortex. Phensuximide's mechanism of action not understood, but may act in inhibitory neuronal systems that are important in the generation of the three per second rhythm. It's effects may be related to its ability to inhibit depolarization-induced accumulation of cyclic AMP and cyclic GMP in brain tissue.   NCATS

Chemistry

  • SMILES: CN1C(=O)CC(C1=O)C2=CC=CC=C2
  • InChIKey: WLWFNJKHKGIJNW-UHFFFAOYSA-N
  • Mol. Mass: 189.2105
  • ALogP: 1.16
  • ChEMBL Molecule:
    phensuximide  
More Chemistry

Pharmacology

Alternative names

fensuccimide | fensuximida | milontin | phensuccimide | phensuximid | phensuximide | phensuximide, (+-)-isomer | phensuximidum | racemic phensuximide | rs-phensuximide | succitimal

Organizations (1)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Epilepsy (approved 1953)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue